Highest development stage: Phase 2

Development active

Gram-negative activity

Mechanism of Action/Target pathogen: multi-drug resistant (MDR) gram-negative bacterial infections, including Carbapenem-resistant Enterobacteriaceae (CRE) and Carbapenem-resistant Pseudomonas aeruginosa(CRPA).